Last Updated : June 30, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Grastofil | Filgrastim | Neutropenia | List with clinical criteria and/or conditions | Complete | ||
| Gynazole.1 | Butoconazole nitrate | Vaginal infection | Do not list | Complete | ||
| Halaven | Eribulin Mesylate | Metastatic Breast Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Harvoni | ledipasvir, sofosbuvir | Hepatitis C, chronic | Reimburse with clinical criteria and/or conditions | Complete | ||
| Harvoni | Ledipasvir / Sofosbuvir | Hepatitis C, chronic | List with criteria/condition | Complete | ||
| Hemangiol | Propranolol oral solution | Infantile hemangioma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Hemangiol | Propranolol | Infantile hemangioma | Withdrawn | |||
| Hemgenix | etranacogene dezaparvovec | Hemophilia B | Reimburse with clinical criteria and/or conditions | Active | ||
| Hemlibra | emicizumab | Bleeding prevention, hemophilia A | Reimburse with clinical criteria and/or conditions | Complete | ||
| Hepsera | Adefovir dipivoxil | Hepatitis B | Do not list | Complete | ||
| Hepsera | Adefovir dipivoxil | Hepatitis B | List with clinical criteria and/or conditions | Complete | ||
| Holkira Pak | ombitasvir/paritaprevir/ritonavir and dasabuvir | Hepatitis C, chronic | Reimburse with clinical criteria and/or conditions | Complete | ||
| Holkira Pak | Ombitasvir/paritaprevir/ritonavir and dasabuvir | Hepatitis C, chronic | List with clinical criteria and/or conditions | Complete | ||
| Humira | Adalimumab | Hidradenitis suppurativa | Reimburse with clinical criteria and/or conditions | Complete | ||
| Humira | Adalimumab | Ulcerative colitis | Do not list at the submitted price | Complete | ||
| Humira | Adalimumab | Arthritis, Rheumatoid | List with clinical criteria and/or conditions | Complete | ||
| Humira | Adalimumab | Arthritis, Psoriatic | List with clinical criteria and/or conditions | Complete | ||
| Humira | Adalimumab | Arthritis, juvenile idiopathic | List with clinical criteria and/or conditions | Complete | ||
| Humira | Adalimumab | ulcerative colitis | Withdrawn | |||
| Humira | Adalimumab | Ankylosing spondylitis (AS) | List with clinical criteria and/or conditions | Complete | ||
| Humira | Adalimumab | Crohn's disease | List with clinical criteria and/or conditions | Complete | ||
| Humira | Adalimumab | Psoriasis | List with clinical criteria and/or conditions | Complete | ||
| HyQvia | immune globulin human and recombinant human hyaluronidase | Humoral immunodeficiency | Reimburse with clinical criteria and/or conditions | Complete | ||
| Ibrance | Palbociclib | Withdrawn | ||||
| Ibrance (with Faslodex) | Palbociclib (with Fulvestrant) | Palbociclib (Ibrance) in combination with fulvestrant for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : June 30, 2024